Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) shareholders, since the share price is down 51% in the last three years, falling well short of the market decline of around 27%.
作爲投資者,值得努力確保您的整體投資組合超過市場平均水平。但是,你會發現有時你會購買該股,但其回報卻低於市場平均水平。遺憾的是,長揸南京證券股份股票的股東不斷髮現其股價下跌,而過去三年的股票下跌幅度超過27%,下跌了51%。
It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.
值得評估公司的經濟狀況是否與這些不盡如人意的股東回報同時發展並步調一致,或者兩者之間是否存在差異。因此,讓我們來看看。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
儘管一些人繼續教授有效市場假說,但已經證明市場是過度反應的動態系統,並且投資者並不總是理性的。通過比較每股收益(EPS)和股價的變化情況,我們可以了解投資者對公司的態度如何隨着時間變化而變化。
Over the three years that the share price declined, Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings per share (EPS) dropped significantly, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
在股價下跌的三年裏,南京金典生物化學制藥股份有限公司每股收益(EPS)顯著下降,降至虧損。由於公司已陷入虧損的位置,很難將EPS的變化與股價的變化進行比較。但是,我們可以說,在這種情況下我們預計會看到股價下跌。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240629/0-dec14ab2d65998f9b04ef6ab43131b46-0-040879f3cabd159072b04a91b842bf5e.png/big)
Dive deeper into Nanjing King-Friend Biochemical PharmaceuticalLtd's key metrics by checking this interactive graph of Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings, revenue and cash flow.
通過查看南京金典生物化學制藥股份有限公司盈利、營業收入和現金流的互動圖表,深入了解該公司的主要指標。
A Different Perspective
不同的觀點
While it's never nice to take a loss, Nanjing King-Friend Biochemical PharmaceuticalLtd shareholders can take comfort that , including dividends,their trailing twelve month loss of 11% wasn't as bad as the market loss of around 16%. Given the total loss of 0.6% per year over five years, it seems returns have deteriorated in the last twelve months. While some investors do well specializing in buying companies that are struggling (but nonetheless undervalued), don't forget that Buffett said that 'turnarounds seldom turn'. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Nanjing King-Friend Biochemical PharmaceuticalLtd , and understanding them should be part of your investment process.
雖然虧損從未是一件好事,但南京金典生物化學制藥股份有限公司的股東可以放心,包括分紅在內,他們過去12個月的虧損率11%並不像市場虧損率16%那樣糟糕。考慮到過去五年總虧損率爲0.6%,似乎回報在過去十二個月出現了下滑。雖然一些投資者在專門購買困境中的公司(但仍被低估)方面做得很好,但不要忘記巴菲特說過的“企穩時反彈很少出現”。雖然考慮市場條件對股價的不同影響是值得的,但還有其他更重要的因素。例如考慮投資風險這一永恒難題。我們已經確定了南京金典生物化學制藥股份有限公司的1個警告信號,了解它們應該成爲你的投資過程的一部分。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com